

Objectives :

1. Reisolation of a virulent strain – in vivo passage of Mmm strain Afade (ILRI)
2. Development of a novel challenge model using a nebulizer fitted with a mask (ILRI and KALRO)
3. Process development and production of a scalable vaccine antigen production (KALRO, MERCK, VIDO)
4. On-Station Efficacy Trial (KALRO)
5. Transmission trial (KALRO)



Clinical trials to develop a subunit vaccine for contagious bovine pleuropneumonia in Kenya




2020 Highlights

Mmm-Colonies and Sample [1309bp]



In vivo passage of virulent strain complete

In vitro testing of viability complete



| | Cfu/ml in nebulizer | Cfu/ml in collection flask |
|-------------|---------------------|----------------------------|
| Timepoint 0 | 3.06E+08 | 8.30E+05 |
| Timepoint 1 | 6.75E+07 | 1.86E+06 |
| Timepoint 2 | 1.06E+08 | 1.43E+06 |
| Timepoint 3 | 3.59E+07 | 4.60E+05 |
| Timepoint 4 | 2.61E+07 | 1.00E+05 |
| Timepoint 5 | 1.03E+07 | 1.41E+05 |
| Timepoint 6 | 5.55E+06 | 3.20E+05 |
| Timepoint 7 | 1.00E+07 | |

In vivo pilot:
2/2 animals challenged via nebulizer developed CBPP

Quick Facts:

Donor: IDRC

Funding: CAD 333, 583 (ILRI)

Duration: Oct 2019-2021

Partners: KALRO, VIDO-InterVac

Extension: 12 months (to be confirmed)

ILRI PI: Elise Schieck

e.schieck@cgiar.org

